The seaberry is a yellow berry cultivated in China, Northern Europe, and West Asian countries. Numerous biological activities of seaberries have been reported, and we recently found that ursolic acid and a flavonoid in seaberry extract (SBE) suppressed the contraction of bladder muscle specimens and collagen gel containing bladder smooth muscle cells. However, the influence of SBE on urinary problems of Japanese adults has not been investigated. Therefore, we conducted a clinical trial of SBE supplementation in Japanese subjects with mild urinary dysfunction.
Figure 1. Flowchart showing the disposition of the subjects

Preparation and allocation of test supplements
The test supplements (indistinguishable brown capsules containing SBE or placebo) were provided by Oryza Oil & Fat Chemical Co., Ltd. The active capsules contained 200 mg of Seaberry Extract-P (seaberry extract powder with 0.09% ursolic acid, Oryza Oil & Fat Chemical Co. Ltd.), while the placebo capsules contained 200 mg of dextrin. Information about the allocation of the test medications was strictly protected by a third-party study treatment/allocation controller who was not directly involved in the study. The information was not disclosed to anybody until the subjects for analysis were determined at a clinical conference after completion of the study.
Study protocol
This randomized placebo-controlled double-blind study was carried out at Takara Clinic (Seishinkai Group, Tokyo), and statistical analysis was done by ORTHOMEDICO Inc. The study was registered with the University Hospital Medical Information Network (UMIN000023486). It involved comparison among three groups receiving concurrent treatment. Subjects in the placebo group and the SBE (400 mg) group took one capsule (placebo or SBE respectively) after breakfast and after dinner. Subjects in the SBE (200 mg) group took one SBE capsule after breakfast and one placebo capsule after dinner. All subjects took the study capsules for 8 weeks and wrote a daily report about capsule ingestion, lifestyle, urination, and menstruation (only women). The primary outcome was the KHQ score, which was determined before treatment and after 4 or 8 weeks of treatment (Table 1) . Nine QOL domains of the KHQ were calculated by the formulae shown in Table 2 . The secondary outcome was the OABSS 21 (Table 3) . Subjects completed the questionnaires and performed blood tests and urine collection before the start of treatment in addition to after 4 and 8 weeks of treatment. Measurement of physical parameters (height, body weight, body mass index (BMI), body fat percentage, blood pressure, and pulse rate) was performed on the same days, and the daily reports of the subjects were collected.
Efficacy and safety of SBE were evaluated from the data obtained as described above. Additionally, urine samples were collected for the qualitative evaluation of protein, glucose, urobilinogen, bilirubin, ketone bodies, pH, and occult blood.
Ethics, adherence, and compliance
This study was performed according to the Declaration of Helsinki (2013 revision) and was carried out in conformity with ethical considerations. The Ethics Committee of ORTHOMEDICO Inc. (an insurance company manager, 2 physicians, 3 nurses, and a lawyer) was convened to deliberate on the ethicality and appropriateness of the study protocol. This study was implemented according to the protocol approved by the Ethics Committee, and any substantial deviations from the protocol required authorization by the committee. All subjects received a full explanation about the protocol and purpose of the study before giving consent to participation.
Investigation of adverse events
Each adverse event was evaluated to determine the causal relationship with the test substance.
Adverse events were defined as clinically significant new physical abnormalities or symptoms that occurred during the study period. If an adverse event occurred, the physician provided appropriate treatment and decided whether the study should be continued. The causal relationship with study treatment was judged according to the following criteria. Table 4 shows the profile of each group. None of the subjects took less than 90% of the prescribed capsules during the study period, so the data on all subjects were used for analysis. Data are represented as the mean ±SD. There were no significant differences between the placebo group and the SBE groups.
RESULTS
Study performance
KHQ score and OABSS
(1) KHQ score Among the nine KHQ domains, the placebo group revealed significant decreases of the scores for "incontinence impact," "role limitations," and "physical limitations" after 8 weeks (Table   5 ). After intake of SBE (200 mg) for 4 weeks, scores for "incontinence impact," "sleep/energy," and "severity/coping" were significantly improved compared to before treatment. Additionally, there was a significant reduction of the "sleep/energy" score after 8 weeks of treatment with SBE (200 mg). After intake of SBE (400 mg) for 8 weeks, the scores for "incontinence impact," "role limitations," "physical limitations," and "severity/coping" were significantly improved compared to before treatment, and the "emotions" score also demonstrated significant improvement compared to the placebo group. 
Q4d. Does your bladder problem limit your ability to see and visit friends?
Q2. How much do you think your bladder problem affects your life?
Q5a. Does your bladder problem affect your relationship with your partner?
Q3a. Does your bladder problem affect your household tasks?
Q5b. Does your bladder problem affect your sex life?
Q3b. Does your bladder problem affect your job, or your normal daily activities outside the home? When the individual items of the KHQ were assessed ( were significantly improved after 8 weeks. In the SBE (400 mg) group, there was significant improvement of the scores for Q2, Q3b, and Q6b after 8 weeks. The scores for Q6a ("Does your bladder problem make you depressed?") and Q6c ("Does your bladder problem make you feel bad about yourself?") showed significant improvement in the SBE (400 mg) group compared to the placebo group.
(2) OABSS As shown in Table 7 , the total OABSS score and the score for Q2 improved at 4 and 8 weeks in the SBE (200 mg) group. In the SBE (400 mg) group, there was significant reduction of the score for Q3 ("How often do you have a sudden desire to urinate, which is difficult to defer?") after 8 weeks compared to the placebo group.
Safety parameters
(1) Blood pressure and pulse rate Assessment of the blood pressure and pulse rate revealed a significant decrease of systolic pressure after 4 weeks in the placebo group. In the SBE groups, there were no significant changes of the blood pressure and pulse rate after 4 and 8 weeks of treatment (Table 8 ).
(2) Laboratory parameters Hematology and biochemical parameters are displayed in Tables 8 and 9 respectively. In the placebo group, MCV and total protein were slightly decreased after 4 and 8 weeks. In the SBE (200 mg/day) group, the red blood cell count was significantly increased after 8 weeks of treatment and a similar change was observed in the SBE (400 mg/day) group at 8 weeks.
Amylase and potassium were increased in the SBE (200 mg/day) group at 8 weeks, while IP was decreased. There were also significant increases of hemoglobin, LDL-cholesterol, γ-GTP, amylase, and potassium in the SBE (400 mg/day) group at 8 weeks, while triglyceride and IP were decreased. However, all of these changes were small and within the normal range.
(3) Urinalysis
Occult blood was detected in the urine of several subjects in each group (Table 10 ). However, investigation by the physician in charge demonstrated that these events were not induced by study treatment. Data are represented as the mean ±SD (n=16). Daggers denote significant differences vs. before ingestion at †: p<0.05 and † †: p<0.01. 
DISCUSSION
Seaberries are known to contain fatty acids, vitamins, polyphenols, and minerals [22] .
Therefore, these berries have been used for nourishment and for treatment of various diseases, including gastrointestinal, skin, and liver conditions [23] . However, the potential health benefits of seaberry ingredients for urinary dysfunction have received little attention. Our previous in vitro study using rat bladder specimens and bladder cells demonstrated that triterpenoids derived from seaberries, including ursolic acid, suppressed excessive bladder contraction [19] .
Overactive bladder (OAB) is an age-related urinary dysfunction syndrome that is especially frequent in women [24] . It may be related to neurologic dysfunction in addition to changes of the bladder musculature [25] . Recent research has shown that OAB symptoms are more severe in women with a high body mass index (BMI) than in those with a normal BMI [26] . In patients with diabetes, high glycosylated hemoglobin levels were also reported to be correlated with OAB [27] . Several questionnaires have been developed for diagnosis and assessment of OAB, including the Beck anxiety inventory (BAI) [28] , OABSS [29] , total urgency and frequency score (TUFS) [30] , and actionable bladder symptom screening tool (ABSST) [31] . In the present study, the KHQ score and OABSS were employed as outcome measures. We found that intake of SBE (400 mg/day) for 8 weeks significantly improved the "Emotions" score in the KHQ, which is calculated from questions related to anxiety about urination. Among the KHQ items, questions 6a ("Does your bladder problem make you depressed?") and 6c ("Does your bladder problem make you feel bad about yourself?") also showed improvement after intake of SBE. Thereby, SBE was confirmed to improve KHQ scores, although the effect was mild. Intake of SBE (400 mg/day) for 8 weeks also improved the OABSS score for "How often do you have a sudden desire to urinate, which is difficult to defer?" According to Nishimura et al. [7] , ingestion of pumpkin seed oil (10 g/day) for 6 to 12 weeks led to improvement of several items related to urgency and frequency of urination in the OABSS. Compared to the effects of pumpkin seed oil they reported, SBE suppressed OAB symptoms at a lower dosage in the present study. Additionally, there were no changes of the blood pressure, laboratory data, and urine parameters after intake of SBE for 8 weeks.
The present study had some limitations. First, this study was performed in healthy subjects who were not on medications for OAB, so the efficacy of SBE for subjects with a high OABSS or KHQ score was not clarified. Second, objective parameters of urinary function were not examined such as the intravesical pressure or residual urine volume. As the mechanism of SBE regarding the suppressive effect, we speculate the involvement of TGF-. Several clinical biomarkers have been reported to change in urinary dysfunction. Urine TGF- elevates in dysfunction of upper urinary tract [32] and is involved in hypertrophy of bladder muscle cells [33] and bladder inflammation [34] . Ursolic acid in SBE is an antagonist of TGF-1 [35] and we confirmed that ursolic acid suppressed gel contraction containing bladder smooth muscle cells induced by TGF-1 [19] . Accordingly, suppression of TGF- action by ursolic acid may be involved in the suppressive mechanism of SBE. However, it is unclear whether the response to SBE was actually based on improvement of OAB or due to an indirect influence on mood.
Therefore, further investigation will be required to assess the objective effect of SBE on urinary function.
In conclusion, oral intake of SBE at 400 mg/day for 8 weeks reduced anxiety related to urination with no adverse effects. This finding suggests that SBE may be a safe and effective plant-derived food ingredient for improving symptoms of OAB.
CONCLUSION
We demonstrated that intake of seaberry extract (400 mg/day for 8 weeks) decreased anxiety related to urination. Therefore, seaberry extract may be useful for controlling symptoms of urinary dysfunction in persons with OAB. OABSS, overactive bladder syndrome score; SBE, seaberry extract; TG, triglyceride; TUFS, total urgency and frequency score.
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